We also found that PD-L1+ myeloma cells had more proliferative potential and were resistant to antimyeloma agents, with higher expression levels of Ki-67 and Bcl-2 compared with PD-L1− myeloma cells [86]. This evidence concerns the gene BCL2 and plasma cell myeloma.